Alzheimer's Research & Therapy | Most Viewed

Submit a manuscript Register Contact us Follow us on Twitter

Explore journal

Advertisement

Articles

Display/download options Articles per page: 25 | 50 | 100

Display options

Editor's summary Citation

Download options

Send
To

	All
	1. 10626 Accesses	Research Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Philippe Robert, Steven Ferris, Serge Gauthier, Ralf Ihl, Bengt Winblad, Frank Tennigkeit Alzheimer's Research & Therapy 2010, 2:24 (26 August 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
	2. 5601 Accesses	Review Alcohol-related dementia: an update of the evidence Nicole J Ridley, Brian Draper, Adrienne Withall Alzheimer's Research & Therapy 2013, 5:3 (25 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ridley and colleagues review the commonality between alcohol-related dementia and alcohol-induced persisting amnestic syndrome in a clinical setting and discuss recommendations for the diagnosis and management of alcohol-related cognitive impairment.
	3. 5528 Accesses	Research Predicting progression of Alzheimer's disease Rachelle S Doody, Valory Pavlik, Paul Massman, Susan Rountree, Eveleen Darby, Wenyaw Chan Alzheimer's Research & Therapy 2010, 2:2 (23 February 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Baseline cognitive assessments of probable Alzheimer’s disease patients can help predict future performance in cognition and activities of daily living, and should be considered when designing clinical trials in Alzheimer’s disease.
	4. 5259 Accesses	Research Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains Brenda D Moore, Paramita Chakrabarty, Yona Levites, Tom L Kukar, Ann-Marie Baine, Tina Moroni, Thomas B Ladd, Pritam Das, Dennis W Dickson, Todd E Golde Alzheimer's Research & Therapy 2012, 4:18 (23 May 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Extensive overlapping between amyloid β (Aβ) levels found in pathological ageing (PA) and Alzheimer's disease (AD) brains indicates that PA represents a prodromal stage of AD or resistance to toxic effects of Aβ.
	5. 4242 Accesses	Research Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study John M Ringman, Sally A Frautschy, Edmond Teng, Aynun N Begum, Jenny Bardens, Maryam Beigi, Karen H Gylys, Vladimir Badmaev, Dennis D Heath, Liana G Apostolova, Verna Porter, Zeba Vanek, Gad A Marshall, Gerhard Hellemann, Catherine Sugar, Donna L Masterman, Thomas J Montine, Jeffrey L Cummings, Greg M Cole Alzheimer's Research & Therapy 2012, 4:43 (29 October 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Oral curcumin did not lead to changes in cognitive examinations or plasma biomarker levels in a 24-week randomized, double blind, placebo-controlled study in patients with Alzheimer disease (AD).
	6. 3787 Accesses	Research Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy Alireza Atri, José L Molinuevo, Ole Lemming, Yvonne Wirth, Irena Pulte, David Wilkinson Alzheimer's Research & Therapy 2013, 5:6 (21 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Combination treatment with memantine added to donepezil provides significant benefits to moderate and moderate-to-severe Alzheimer's disease patients in meta-analyses of data from two 24-week, randomised, double-blind, placebo-controlled trials.
	7. 3689 Accesses	Commentary Mild traumatic brain injury: a risk factor for neurodegeneration Brandon E Gavett, Robert A Stern, Robert C Cantu, Christopher J Nowinski, Ann C McKee Alzheimer's Research & Therapy 2010, 2:18 (25 June 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| 1 comment \| Editor’s summary Head trauma can lead to progressive neurodegeneration and further study of this risk factor could help us improve prevention and treatment strategies for other neurodegenerative diseases.
	8. 3599 Accesses	Research The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice Marguerite Prior, Richard Dargusch, Jennifer L Ehren, Chandramouli Chiruta, David Schubert Alzheimer's Research & Therapy 2013, 5:25 (14 May 2013) Abstract \| Provisional PDF \| PubMed \| Editor’s summary Novel drug candidate J147 is able to arrest and reverse memory deficits and improve several aspects of brain function in aged mice with advanced symptoms of Alzheimer's disease (AD).
	9. 3553 Accesses	Editorial Recent Alzheimer's disease research highlights Douglas Galasko, Todd Golde, Gordon Wilcock Alzheimer's Research & Therapy 2012, 4:14 (18 May 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary In their editorial, Editors-in-Chief Douglas Galasko, Todd Golde and Gordon Wilcock highlight several of the major translational research advances in Alzheimer's disease (AD) that have occurred over the past year.
	10. 3489 Accesses	Review Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy Elina Zotova, James AR Nicoll, Raj Kalaria, Clive Holmes, Delphine Boche Alzheimers Res Ther 2010, 2:1 (22 January 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Zotova et al. review the immune processes involved in Alzheimer’s disease pathogenesis and highlight the importance of addressing neuro-immune interactions when devising therapeutic strategies.
	11. 3364 Accesses	Research Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease Guriqbal S Basi, Susanna Hemphill, Elizabeth F Brigham, Anna Liao, Danielle L Aubele, Jeanne Baker, Robin Barbour, Michael Bova, Xiao-Hua Chen, Michael S Dappen, Tovah Eichenbaum, Erich Goldbach, Jon Hawkinson, Rose Lawler-Herbold, Kang Hu, Terence Hui, Jacek J Jagodzinski, Pamela S Keim, Dora Kholodenko, Lee H Latimer, Mike Lee, Jennifer Marugg, Matthew N Mattson, Scott McCauley, James L Miller, Ruth Motter, Linda Mutter, Martin L Neitzel, Huifang Ni, Lan Nguyen et al. Alzheimer's Research & Therapy 2010, 2:36 (29 December 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary An amyloid precursor protein selective gamma-secretase inhibitor demonstrates selectivity for inhibiting Amyloid beta production in Alzheimer’s disease transgenic mice and needs to be corroborated in wild-type mice.
	12. 3246 Accesses	Review Ayurvedic medicinal plants for Alzheimer's disease: a review Rammohan V Rao, Olivier Descamps, Varghese John, Dale E Bredesen Alzheimer's Research & Therapy 2012, 4:22 (29 June 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Rao and colleagues review the potential of various Ayurvedic medicinal plants to reverse Alzheimer's disease pathology, summarizing recent information on their phytochemical, biological and cellular activities and clinical applications.
	13. 3210 Accesses	Review Alzheimer's disease diagnostic criteria: practical applications Jeffrey Cummings Alzheimer's Research & Therapy 2012, 4:35 (5 September 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Jeffrey Cummings reviews the advantages and limitations of the IWG and NIA/AA Alzheimer's disease (AD) diagnostic criteria, and discusses improvements for future revisions.
	14. 3065 Accesses	Review Neuropsychiatric features of C9orf72-associated behavioral variant frontotemporal dementia and frontotemporal dementia with motor neuron disease Leonel T Takada, Sharon J Sha Alzheimer's Research & Therapy 2012, 4:38 (3 October 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Takada and Sha review the neuropsychiatric features of chromosome 9p-linked frontotemporal dementia (FTD) and the risk that some C9orf72 mutation carriers may be misdiagnosed with primary psychiatric conditions.
	15. 2764 Accesses	Review Dementia prevention: current epidemiological evidence and future perspective Francesca Mangialasche, Miia Kivipelto, Alina Solomon, Laura Fratiglioni Alzheimer's Research & Therapy 2012, 4:6 (13 February 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Mangialasche and colleagues address current epidemiological research and intervention studies to identify promising preventative strategies for Alzheimer's disease (AD) and dementia; considering the need for randomized controlled trials to confirm these findings.
	16. 2713 Accesses	Research Dystrophic neurites express C9orf72 in Alzheimer's disease brains Jun-ichi Satoh, Hiroko Tabunoki, Tsuyoshi Ishida, Yuko Saito, Kunimasa Arima Alzheimer's Research & Therapy 2012, 4:33 (16 August 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary C9orf72 and UBQLN-1 expression in a cluster of dystrophic neurites in senile plaques in Alzheimer's disease brains suggests C9orf72 has a role in the process of neurodegeneration.
	17. 2689 Accesses	Research CLU, CR1 and PICALM genes associate with Alzheimer's-related senile plaques Eloise H Kok, Teemu Luoto, Satu Haikonen, Sirkka Goebeler, Hannu Haapasalo, Pekka J Karhunen Alzheimer's Research & Therapy 2011, 3:12 (5 April 2011) Abstract \| Full text \| PDF \| PubMed \| 1 comment \| Editor’s summary CLU, CR1 and PICALM genes are not strongly related to senile plaque prevalence, or at all to neurofibrillary tangles, and most likely do not affect the development of these Alzheimer’s disease (AD) lesions.
	18. 2639 Accesses	Commentary Herbal therapy: a new pathway for the treatment of Alzheimer's disease Jinzhou Tian, Jing Shi, Xuekai Zhang, Yongyan Wang Alzheimer's Research & Therapy 2010, 2:30 (22 October 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| 1 comment \| Editor’s summary On the basis of current evidence, Tian and colleagues discuss whether herbal therapy could be a novel pathway to treat Alzheimer’s disease (AD) and the implications of these results on future therapy development.
	19. 2624 Accesses	Research Predictors of long-term cognitive outcome in Alzheimer's disease Carina Wattmo, Åsa K Wallin, Elisabet Londos, Lennart Minthon Alzheimer's Research & Therapy 2011, 3:23 (20 July 2011) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Clinical predictors of a more favorable longitudinal outcome in Alzheimer's disease include male gender, older age, absence of the apolipoprotein E e4 allele, treatment with non-steroidal anti-inflammatory drugs or a higher mean dose of cholinesterase inhibitor.
	20. 2590 Accesses	Review The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? Kerensa Broersen, Frederic Rousseau, Joost Schymkowitz Alzheimer's Research & Therapy 2010, 2:12 (14 July 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Amyloid beta has been identified as neurotoxic in patients with Alzheimer’s disease (AD), but we must take into account its structural characteristics, as well as size, when exploring AD development.
	21. 2583 Accesses	Research Systematic reviews on behavioural and psychological symptoms in the older or demented population Rianne M van der Linde, Blossom CM Stephan, George M Savva, Tom Dening, Carol Brayne Alzheimer's Research & Therapy 2012, 4:28 (11 July 2012) Abstract \| Full text \| PDF \| PubMed
	22. 2578 Accesses	Review Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease Adam Kline Alzheimer's Research & Therapy 2012, 4:32 (27 August 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Adam Kline discusses therapeutic approaches targeting apolipoprotein E (apoE), the most significant risk factor for non-familial Alzheimer's disease (AD), including key interactions of apoE and amyloid-beta pathology and preclinical animal models.
	23. 2561 Accesses	Research ¹⁸F-florbetaben Aβ imaging in mild cognitive impairment Kevin Ong, Victor L Villemagne, Alex Bahar-Fuchs, Fiona Lamb, Gaël Chételat, Parnesh Raniga, Rachel S Mulligan, Olivier Salvado, Barbara Putz, Katrin Roth, Colin L Masters, Cornelia B Reininger, Christopher C Rowe Alzheimer's Research & Therapy 2013, 5:4 (16 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Higher levels of amyloid-β deposition, measured using 18F-florbetaben imaging, was associated with more severe memory loss in mild cognitive impairment (MCI) patients, proving its utility in early MCI diagnosis.
	24. 2504 Accesses	Review Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases Todd E Golde, Victor M Miller Alzheimers Res Ther 2009, 1:5 (12 October 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Golde and Miller propose an integrative hypothesis that provides new insights into how a variety of misfolded protein aggregates can result in neurodegeneration.
	25. 2465 Accesses	Research Factors that influence survival in a probable Alzheimer disease cohort Susan D Rountree, Wenyaw Chan, Valory N Pavlik, Eveleen J Darby, Rachelle S Doody Alzheimer's Research & Therapy 2012, 4:16 (15 May 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Multiple factors influence survival in a large Alzheimer's disease (AD) cohort and the rate of cognitive decline at the initial patient visit is an important mortality predictor.